Agios Pharmaceuticals, Inc. earnings per share and revenue
On Oct 30, 2025, AGIO reported earnings of -1.78 USD per share (EPS) for Q3 25, beating the estimate of -1.93 USD, resulting in a 8.09% surprise. Revenue reached 12.88 million, compared to an expected 10.63 million, with a 21.22% difference. The market reacted with a +2.91% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -1.98 USD, with revenue projected to reach 12.25 million USD, implying an increase of 11.24% EPS, and decrease of -4.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Agios Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Agios Pharmaceuticals, Inc. reported EPS of -$1.78, beating estimates by 8.09%, and revenue of $12.88M, 21.22% above expectations.
How did the market react to Agios Pharmaceuticals, Inc.'s Q3 2025 earnings?
The stock price moved up 2.91%, changed from $41.96 before the earnings release to $43.18 the day after.
When is Agios Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Agios Pharmaceuticals, Inc.'s next earnings report?
Based on 12
analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.98 and revenue of $12.25M for Q4 2025.